These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24369334)

  • 21. A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections.
    Ebringer A; Rashid T; Tiwana H; Wilson C
    Clin Rheumatol; 2007 Mar; 26(3):289-97. PubMed ID: 16941202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sibship Crohn's disease and ankylosing spondylitis.
    Gilvarry J; Keeling F; Fielding JF
    J Clin Gastroenterol; 1990 Dec; 12(6):711-2. PubMed ID: 2266254
    [No Abstract]   [Full Text] [Related]  

  • 23. Mediterranean spotted fever in a patient with Crohn's disease under adalimumab: First case report and review of the literature.
    Santos-Antunes J; Nunes AC; Macedo G
    Gastroenterol Hepatol; 2015; 38(6):379-80. PubMed ID: 25073681
    [No Abstract]   [Full Text] [Related]  

  • 24. [The association between ankylosing spondylitis, Crohn's disease and HLA-B27. A study of seven patients].
    Mulero J; Abreu L; Chantar C; Cruz J; Barrios C; Noguera E
    Med Clin (Barc); 1982 Jun; 79(1):27-30. PubMed ID: 6981742
    [No Abstract]   [Full Text] [Related]  

  • 25. Distinct immune signatures in the colon of Crohn's disease and ankylosing spondylitis patients in the absence of inflammation.
    Dunn ET; Taylor ES; Stebbings S; Schultz M; Butt AG; Kemp RA
    Immunol Cell Biol; 2016 May; 94(5):421-9. PubMed ID: 26647966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interdependence of ankylosing spondylitis and Crohn's disease].
    Lysy Y; Branski D
    Harefuah; 1986 Jan; 110(1):26-7. PubMed ID: 3485554
    [No Abstract]   [Full Text] [Related]  

  • 27. Rosacea in Crohn's Disease: Effect of Rifaximin.
    Weinstock LB
    J Clin Gastroenterol; 2011 Mar; 45(3):295-6. PubMed ID: 21278581
    [No Abstract]   [Full Text] [Related]  

  • 28. Histocompatibility antigens and other markers in ankylosing spondylitis and inflammatory bowel diseases.
    van dan Berg-Loonen PM; Dekker-Saeys AJ; Meuwissen SG; Nijenhuis LE
    J Rheumatol Suppl; 1977; 3():57-9. PubMed ID: 266599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulomatous ileitis in a patient with ankylosing spondylitis.
    Adebayo D; Popat R; Thjodleifsson B; Bjarnason I
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jun; 4(6):347-51. PubMed ID: 17541448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.
    Cooper R; Fraser SM; Sturrock RD; Gemmell CG
    Br Med J (Clin Res Ed); 1988 May; 296(6634):1432-4. PubMed ID: 3132277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linking Crohn's disease and ankylosing spondylitis: it's all about genes!
    Elewaut D
    PLoS Genet; 2010 Dec; 6(12):e1001223. PubMed ID: 21152009
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of colitis ulcerosa and Crohn's disease].
    Kovács A
    Orv Hetil; 2006 Apr; 147(16):755-8. PubMed ID: 16711262
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27,B44.
    Purrmann J; Zeidler H; Bertrams J; Juli E; Cleveland S; Berges W; Gemsa R; Specker C; Reis HE
    J Rheumatol; 1988 Nov; 15(11):1658-61. PubMed ID: 3266250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging therapeutic targets and strategies in Crohn's disease.
    Furfaro F; Fiorino G; Allocca M; Gilardi D; Danese S
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):735-44. PubMed ID: 26766496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
    Hanauer SB; Sandborn WJ; Lichtenstein GR
    Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Determination of endotoxin in inflammatory rheumatic diseases--the effect of nonsteroidal anti-inflammatory agents on intestinal permeability].
    Busch J; Hammer M; Brunkhorst R; Wagener P
    Z Rheumatol; 1988; 47(3):156-60. PubMed ID: 3213262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Potential of Amino Acids in Inflammatory Bowel Disease.
    Liu Y; Wang X; Hu CA
    Nutrients; 2017 Aug; 9(9):. PubMed ID: 28832517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of Crohn's disease after intestinal resection].
    Bettenworth D; Dignass A
    Z Gastroenterol; 2015 Aug; 53(8):843-5. PubMed ID: 26284331
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.